Skip to main content
Erschienen in: Advances in Therapy 1/2021

24.11.2020 | Commentary

Caregivers’ and Physicians’ Perspectives on Alpha-Mannosidosis: A Report from Italy

verfasst von: Elena Verrecchia, Ludovico L. Sicignano, Maria Grazia Massaro, Rossana Rocco, Gabriella Silvestri, Silvia Rossi, Raffaele Manna

Erschienen in: Advances in Therapy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Alpha-mannosidosis is a rare lysosomal storage disorder that generally presents in early childhood. It is a progressive, highly heterogeneous disease that is difficult to recognize, and a diagnosis is usually reached after referrals to multiple specialists. It is important to understand the challenges faced by patients and their caregiver up to and after a diagnosis of alpha-mannosidosis. In this report, we describe the process of alpha-mannosidosis diagnosis and treatment from the caregivers’ and physicians’ perspectives. For the caregivers’ perspective, the mothers of two patients with alpha-mannosidosis (‘Adele’ aged 35 years and ‘Amedeo’ aged 40 years) were interviewed in their homes in Italy, and anonymized transcripts were used to describe their experiences. Adele lived in a large city with access to hospitals and specialized centers and was diagnosed with alpha-mannosidosis before 3 years of age. Amedeo was from a small village and was diagnosed when he was 10–11 years old. In both cases, their mothers sought help from pediatricians and other specialists for recurrent infections and delayed speech and motor development in the first years of their lives, but diagnosis was delayed. Although the diagnostic pathway was concerning and frustrating for her mother, Adele was able to live at home and receive multidisciplinary care and psychosocial support locally, but the transition from pediatric to adult services was difficult. She is currently waiting for access to enzyme replacement therapy. Amedeo had to travel widely and frequently to receive a diagnosis and access supportive treatment. The cumulative morbidity resulting from the delays and poor access to care necessitated long-term residential care. From the physicians’ perspective, greater awareness of alpha-mannosidosis is required among healthcare professionals and more support is needed for patients and caregivers, particularly those living in rural areas or small centers.
Literatur
1.
Zurück zum Zitat Malm D, Nilssen Ø. Alpha-mannosidosis. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, editors. GeneReviews®. Seattle (WA): University of Washington; 2001. Malm D, Nilssen Ø. Alpha-mannosidosis. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, editors. GeneReviews®. Seattle (WA): University of Washington; 2001.
2.
Zurück zum Zitat Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21.CrossRef Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21.CrossRef
3.
Zurück zum Zitat Adam J, Malone R, Lloyd S, Lee J, Hendriksz CJ, Ramaswami U. Disease progression of alpha-mannosidosis and impact on patients and carers—a UK natural history survey. Mol Genet Metab Rep. 2019;20:100480.CrossRef Adam J, Malone R, Lloyd S, Lee J, Hendriksz CJ, Ramaswami U. Disease progression of alpha-mannosidosis and impact on patients and carers—a UK natural history survey. Mol Genet Metab Rep. 2019;20:100480.CrossRef
4.
Zurück zum Zitat Beck M, Olsen KJ, Wraith JE, et al. Natural history of alpha mannosidosis a longitudinal study. Orphanet J Rare Dis. 2013;8:88.CrossRef Beck M, Olsen KJ, Wraith JE, et al. Natural history of alpha mannosidosis a longitudinal study. Orphanet J Rare Dis. 2013;8:88.CrossRef
5.
Zurück zum Zitat Malm D, Riise Stensland HM, Edvardsen O, Nilssen O. The natural course and complications of alpha-mannosidosis—a retrospective and descriptive study. J Inherit Metab Dis. 2014;37(1):79–82.CrossRef Malm D, Riise Stensland HM, Edvardsen O, Nilssen O. The natural course and complications of alpha-mannosidosis—a retrospective and descriptive study. J Inherit Metab Dis. 2014;37(1):79–82.CrossRef
6.
Zurück zum Zitat Finocchiaro D, Rastelletti I, De-Almeida J, Lloyd S, Gupta P. A systematic review of the epidemiology of alpha-mannosidosis [abstract PSY26]. Value Health. 2018;21:S249.CrossRef Finocchiaro D, Rastelletti I, De-Almeida J, Lloyd S, Gupta P. A systematic review of the epidemiology of alpha-mannosidosis [abstract PSY26]. Value Health. 2018;21:S249.CrossRef
7.
Zurück zum Zitat Lehalle D, Colombo R, O’Grady M, et al. Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: report of seven new cases. Am J Med Genet A. 2019;179(9):1756–63.CrossRef Lehalle D, Colombo R, O’Grady M, et al. Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: report of seven new cases. Am J Med Genet A. 2019;179(9):1756–63.CrossRef
8.
Zurück zum Zitat Wiesinger T, Schwarz M, Mechtler TP, Liebmann-Reindl S, Streubel B, Kasper DC. α-Mannosidosis—an underdiagnosed lysosomal storage disease in individuals with an “MPS-like” phenotype. Mol Genet Metab. 2020;130(2):149–52.CrossRef Wiesinger T, Schwarz M, Mechtler TP, Liebmann-Reindl S, Streubel B, Kasper DC. α-Mannosidosis—an underdiagnosed lysosomal storage disease in individuals with an “MPS-like” phenotype. Mol Genet Metab. 2020;130(2):149–52.CrossRef
9.
Zurück zum Zitat Guffon N, Tylki-Szymanska A, Borgwardt L, et al. Recognition of alpha-mannosidosis in paediatric and adult patients: presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019;126(4):470–4.CrossRef Guffon N, Tylki-Szymanska A, Borgwardt L, et al. Recognition of alpha-mannosidosis in paediatric and adult patients: presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019;126(4):470–4.CrossRef
10.
Zurück zum Zitat Zielonka M, Garbade SF, Kolker S, Hoffmann GF, Ries M. Ultra-orphan lysosomal storage diseases: a cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis. 2019;42(5):975–83.CrossRef Zielonka M, Garbade SF, Kolker S, Hoffmann GF, Ries M. Ultra-orphan lysosomal storage diseases: a cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis. 2019;42(5):975–83.CrossRef
12.
Zurück zum Zitat Harmatz P, Cattaneo F, Ardigo D, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab. 2018;124(2):152–60.CrossRef Harmatz P, Cattaneo F, Ardigo D, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab. 2018;124(2):152–60.CrossRef
13.
Zurück zum Zitat Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215–23.CrossRef Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215–23.CrossRef
14.
Zurück zum Zitat Borgwardt L, Lund A, Amraoui Y, et al. Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis [abstract 39]. Mol Genet Metab. 2017;120:S30.CrossRef Borgwardt L, Lund A, Amraoui Y, et al. Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis [abstract 39]. Mol Genet Metab. 2017;120:S30.CrossRef
15.
Zurück zum Zitat Lund AM, Borgwardt L, Cattaneo F, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225–33.CrossRef Lund AM, Borgwardt L, Cattaneo F, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225–33.CrossRef
16.
Zurück zum Zitat Phillips D, Hennermann JB, Tylki-Szymanska A, et al. Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis. Mol Genet Metab Rep. 2020;23:100586.CrossRef Phillips D, Hennermann JB, Tylki-Szymanska A, et al. Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis. Mol Genet Metab Rep. 2020;23:100586.CrossRef
17.
Zurück zum Zitat Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterniary use and establishing a European Medicines Agency, Article 83 (2004). Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterniary use and establishing a European Medicines Agency, Article 83 (2004).
18.
Zurück zum Zitat Gelb MH. Newborn screening for lysosomal storage diseases: methodologies, screen positive rates, normalization of datasets, second-tier tests, and post-analysis tools. Int J Neonatal Screen. 2018;4(3):23.CrossRef Gelb MH. Newborn screening for lysosomal storage diseases: methodologies, screen positive rates, normalization of datasets, second-tier tests, and post-analysis tools. Int J Neonatal Screen. 2018;4(3):23.CrossRef
19.
Zurück zum Zitat Kumar AB, Hong X, Yi F, Wood T, Gelb MH. Tandem mass spectrometry-based multiplex assays for alpha-mannosidosis and fucosidosis. Mol Genet Metab. 2019;127(3):207–11.CrossRef Kumar AB, Hong X, Yi F, Wood T, Gelb MH. Tandem mass spectrometry-based multiplex assays for alpha-mannosidosis and fucosidosis. Mol Genet Metab. 2019;127(3):207–11.CrossRef
Metadaten
Titel
Caregivers’ and Physicians’ Perspectives on Alpha-Mannosidosis: A Report from Italy
verfasst von
Elena Verrecchia
Ludovico L. Sicignano
Maria Grazia Massaro
Rossana Rocco
Gabriella Silvestri
Silvia Rossi
Raffaele Manna
Publikationsdatum
24.11.2020
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 1/2021
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01574-w

Weitere Artikel der Ausgabe 1/2021

Advances in Therapy 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.